NICE green lights Roche’s Rozlytrek for NTRK tumours

The UK’s National Institute for Health and Care Excellence (NICE) has cleared Roche’s Rozlytrek for NTRK fusion-positive solid tumours, shortly after clearing a rival drug from

Tumour-agnostic drugs ‘game-changing’, says NICE as it rejec...

Bayer’s Vitrakvi is first tumour-agnostic drug approved in E...